The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

This study (PODIUM) is comparing three targeted treatments — vedolizumab, ustekinumab, and JAK inhibitors (such as tofacitinib or upadacitinib) — for people with ulcerative colitis (UC) whose condition did not respond well enough to anti-TNF drugs (like infliximab or adalimumab), a common first targeted treatment for UC. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of ulcerative colitis - Your UC is currently active and causing symptoms - You have already tried and not responded adequately to at least one anti-TNF drug (like infliximab or adalimumab) - You are starting one of the three study medications (vedolizumab, ustekinumab, or a JAK inhibitor) as your next treatment **You may NOT be eligible if...** - You have Crohn's disease (not UC) - You have never tried anti-TNF therapy - You have active serious infections or other conditions that prevent treatment Talk to your doctor to see if this trial is right for you.